全文获取类型
收费全文 | 54849篇 |
免费 | 5218篇 |
国内免费 | 2582篇 |
专业分类
耳鼻咽喉 | 103篇 |
儿科学 | 3425篇 |
妇产科学 | 250篇 |
基础医学 | 4791篇 |
口腔科学 | 452篇 |
临床医学 | 4784篇 |
内科学 | 11037篇 |
皮肤病学 | 520篇 |
神经病学 | 1358篇 |
特种医学 | 1375篇 |
外国民族医学 | 7篇 |
外科学 | 21764篇 |
综合类 | 6240篇 |
现状与发展 | 15篇 |
一般理论 | 2篇 |
预防医学 | 902篇 |
眼科学 | 1254篇 |
药学 | 1767篇 |
10篇 | |
中国医学 | 285篇 |
肿瘤学 | 2308篇 |
出版年
2024年 | 89篇 |
2023年 | 820篇 |
2022年 | 1050篇 |
2021年 | 1818篇 |
2020年 | 1916篇 |
2019年 | 2078篇 |
2018年 | 2125篇 |
2017年 | 1952篇 |
2016年 | 1890篇 |
2015年 | 1846篇 |
2014年 | 3067篇 |
2013年 | 3596篇 |
2012年 | 2572篇 |
2011年 | 3181篇 |
2010年 | 2945篇 |
2009年 | 3030篇 |
2008年 | 3128篇 |
2007年 | 3316篇 |
2006年 | 3310篇 |
2005年 | 2912篇 |
2004年 | 2390篇 |
2003年 | 2013篇 |
2002年 | 1632篇 |
2001年 | 1374篇 |
2000年 | 1191篇 |
1999年 | 921篇 |
1998年 | 848篇 |
1997年 | 733篇 |
1996年 | 684篇 |
1995年 | 575篇 |
1994年 | 631篇 |
1993年 | 379篇 |
1992年 | 484篇 |
1991年 | 331篇 |
1990年 | 238篇 |
1989年 | 257篇 |
1988年 | 240篇 |
1987年 | 160篇 |
1986年 | 133篇 |
1985年 | 146篇 |
1984年 | 129篇 |
1983年 | 55篇 |
1982年 | 83篇 |
1981年 | 73篇 |
1980年 | 64篇 |
1979年 | 44篇 |
1978年 | 45篇 |
1977年 | 39篇 |
1976年 | 37篇 |
1973年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
目的 研究转酪氨酸激酶C(tyrosine kinase C,TrkC)基因神经干细胞(neural stem cells,NSCs)移植治疗脊髓损伤的作用。方法 60只SD大鼠随机分成正常对照组(A组)、脊髓半切组(B组)、NSCs移植组(C组)、NSCs移植+神经营养素(NT)-3局部使用(D)组、转TrkC基WNSCs移植组(E组)和转TrkC基因NSCs移植+NT-3局部使用组(F组),每组10只。脊髓损伤后第9天进行细胞移植。各组大鼠在细胞移植后2个月,行体感诱发电位(SEP)和运动诱发电位(MEP)检查以及脊髓运动功能(BBB)评分。结果 细胞移植后2个月SEP和MEP发生潜伏期和峰峰波幅以及右后肢BBB评分的恢复均以下组最佳,与其他各组比较,差异有统计学意义(P< 0.05,0.01)。结论在局部给予的NT-3作用下,转TrkC基因NSCs能较好地促进损伤脊髓功能的恢复。 相似文献
102.
103.
104.
目的探讨犬双肺序贯性移植时供肺的采取及受体移植手术技巧。方法犬16条,体重差异<5%的随机配对作为供受体进行双肺序贯移植实验共8次,移植右肺钳夹左房时采用了‘v’钳夹技术,并检测左肺及右肺术后0.5、1、2 h各进行血气分析、肺水含量及电镜下超微结构,了解术后肺功能。结果移植右肺时采取的‘v’型钳夹术良好地解决了钳夹左房时因回心血量受阻而引起的心功能不全。术后检测结果表明移植后肺功能良好。结论掌握了犬双肺序贯性移植的全过程,"V"形双阻断钳夹左心房技术提高了犬肺移植的成功率。 相似文献
105.
目的探讨大鼠脂肪来源间充质干细胞(MSC)对大鼠肝移植术后急性排斥反应的作用。方法分离、培养SD大鼠MSC,体外混合淋巴细胞培养(MLC)体系中,研究MSC对Wistar大鼠T细胞增殖的抑制作用。以SD与Wistar大鼠为供受体建立肝移植模型。随机分为MSC处理组与空白对照组,术后第7天检测肝功能、血清白细胞介素(IL)-2和白细胞介素(IL)-10水平、肝组织病理形态及肝细胞凋亡。结果体外MLC中,Wistar大鼠T细胞增殖明显受抑,抑制率为48.44%。实验组血清丙氨酸转氨酶(ALT)、天冬氨酸转氨酶(AST)、总胆红素(TBIL)、IL-2、IL-10分别为(134.2±45.0)、(162.5±30.5)U/L、(30.6±5.4)μmol/L、(187.35±18.26)、(193.95±37.62)μg/L;对照组上述指标分别为(355.6±54.3)、(296.4±71.2)U/L、(145.7±28.6)μmoL/L、(295.73±57.15)、(75.12±11.23)μg/L,两组差异有统计学意义(P<0.05);病检提示实验组排斥反应较对照组明显减轻;脱氧脲核苷酸缺口末端标记(TUNEL)检测提示实验组肝细胞凋亡程度明显低于对照组(P<0.05)。结论供体来源MSC能明显抑制MLC体系中受体源T细胞的增殖,并能显著减轻大鼠肝移植术后急性排斥反应。 相似文献
106.
目的 观察共刺激分子阻断剂CD80单克隆抗体(CD80mAb)在协同未成熟树突细胞(imDC)诱导同种异体大鼠胰十二指肠移植免疫耐受中的作用。方法 建立糖尿病大鼠胰十二指肠移植动物模型;4E5杂交瘤细胞株BABIMC小鼠腹腔注射,抽取腹水,分离纯化后获得CD80mAb;分离供体大鼠骨髓来源DC细胞前体,经GM—CSF、IL-4体外刺激后。再加入IL-10共培养,鉴定为imDC;移植前7d,将2×10^6imDC经静脉途径注射至受体体内,同时分别给予生理盐水1ml、CD80mAb5mg连续14d。结果 四组受体大鼠移植后中位生存时间分别为12.7d、32.4d、50.2d、92.0d,实验组存活时间明显延长;组织学观察发现移植后7dCD80mAb+imDC组移植物形态尚完整,淋巴细胞浸润减少;混合淋巴细胞反应证实移植后7dCD80mAb+imDC组供受体间呈低反应性。结论 共刺激分子阻断剂CD80mAb能够协同imDC诱导受体T细胞对移植物的免疫耐受,降低宿主对移植物的急、慢性排斥反应,延长移植物的存活时间。 相似文献
107.
Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years 总被引:2,自引:0,他引:2
Christopher J. E. Watson J. Andrew Bradley Peter J. Friend John Firth Craig J. Taylor John R. Bradley Kenneth G. C. Smith Sathia Thiru Neville V. Jamieson Geoff Hale Herman Waldmann Roy Calne 《American journal of transplantation》2005,5(6):1347-1353
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper describes 5-year results of a single center study of alemtuzumab as induction in renal transplantation. Thirty-three renal transplant recipients received 20 mg alemtuzumab on day 0 and 1, followed by half-dose cyclosporin monotherapy (trough concentration 75-125 ng/mL) from day 3. They were compared in a retrospective contemporaneous-controlled manner with 66 kidney transplant recipients transplanted in the same period and center who received conventional immunosuppression with cyclosporin, azathioprine and prednisolone. In the alemtuzumab group 12% of recipients died compared to 17% in the control group (p = 0.48); likewise graft loss was similar in both groups (21% vs. 26%, respectively, p = 0.58). Incidence of acute rejection was also comparable at 5 years (31.5% vs. 33.6%), although the pattern of rejection was different with 14% patients in the alemtuzumab group experiencing rejection over 1 year post-transplant compared to none in the control group. There was no significant difference between groups in terms of infection or serious adverse events. While acknowledging the limitations of a relatively small single-center study, results suggest that alemtuzumab induction allowed satisfactory long-term patient and graft survival equivalent to that seen with standard triple immunosuppression, while avoiding steroid therapy. 相似文献
108.
Y. Le Meur M. Büchler A. Thierry S. Caillard F. Villemain S. Lavaud I. Etienne P.-F. Westeel B. H. de Ligny L. Rostaing E. Thervet J. C. Szelag J.-P. Rérolle A. Rousseau G. Touchard P. Marquet 《American journal of transplantation》2007,7(11):2496-2503
Efficacy and safety of mycophenolate mofetil (MMF) may be optimized with individualized doses based on therapeutic monitoring of its active metabolite, mycophenolic acid (MPA). In this 12-month study, 137 renal allograft recipients from 11 French centers receiving basiliximab, cyclosporine A, MMF and corticosteroids were randomized to receive either concentration-controlled doses or fixed-dose MMF. A novel Bayesian estimator of MPA AUC based on three-point sampling was used to individualize doses on posttransplant days 7 and 14 and months 1, 3 and 6. The primary endpoint was treatment failure (death, graft loss, acute rejection and MMF discontinuation). Data from 65 patients/group were analyzed. At month 12, the concentration-controlled group had fewer treatment failures (p = 0.03) and acute rejection episodes (p = 0.01) with no differences in adverse event frequency. The MMF dose was higher in the concentration-controlled group at day 14 (p < 0.0001), month 1 (p < 0.0001) and month 3 (p < 0.01), as were median AUCs on day 14 (33.7 vs. 27.1 mg*h/L; p = 0.0001) and at month 1 (45.0 vs. 30.9 mg*h/L; p < 0.0001). Therapeutic MPA monitoring using a limited sampling strategy can reduce the risk of treatment failure and acute rejection in renal allograft recipients 12 months posttransplant with no increase in adverse events. 相似文献
109.
M. Diez L. Favaloro A. Bertolotti J. M. Burgos C. Vigliano M. P. Lastra M. J. Levin A. Arnedo C. Nagel A. G. Schijman R. R. Favaloro 《American journal of transplantation》2007,7(6):1633-1640
Heart transplantation (HTx) is a useful therapy for end‐stage Chaga? cardiomyopathy; however, Chagas reactivation remains a mayor complication. Parasitological methods offer poor diagnostic sensitivity, and use of more sensitive tools such as the Polymerase chain reaction (PCR) is usually necessary. In the present study, reactivation incidence and PCR usefulness for early reactivation diagnosis, as well as for treatment response evaluation during follow‐up, were analyzed using Strout parasite detection test, in 10 of 222 consecutive HTx patients suffering Chagas cardiomyopathy. PCR strategies targeted to minicircle sequences (kDNA, detection limit 1 parasite/ 10 mL blood) and miniexon genes (SL‐DNA, 200 parasite/10 mL) were performed to compare parasite burdens between samples. No patients received prophylactic antiprotozoal therapy (benznidazole). Five patients (50%) exhibited clinical reactivation within a mean period of 71.6 days; positive Strout results were observed in most cases presenting clinical manifestations. kDNA‐PCR was positive 38–85 days before reactivation, whereas SLDNA‐PCR became positive only 7–21 days later, revealing post‐HTx parasitic load enhancement present prior to clinical reactivation development. Reactivations were successfully treated with benznidazole and generated negative PCR results. Results observed in this study indicate the value of PCR testing for an early diagnosis of Chagas reactivation as well as for monitoring treatment efficacy. 相似文献
110.
The greatest benefit of immunosuppression minimization for children may lie in improving patient morbidity, by the elimination of the inherent side effects of steroid and calcineurin inhibitors (CNI). The newer generation of powerful induction and maintenance immunosuppressants offers an option for selected immunosuppression minimization strategies, some of which have been shown to also reduce graft morbidity. Steroid minimization and avoidance in single-center uncontrolled trials have shown early promise and the availability of data from an ongoing randomized, prospective, controlled trial of steroid avoidance in children will provide necessary data to support a practice change for steroid elimination in children. Calcineurin inhibitor minimization and addition of mycophenolate mofetil (MMF) or sirolimus have shown variable improvements in renal function, though suboptimal efficacy and safety with the currently proposed regimes have limited their application. Randomized, prospective studies of steroid and calcineurin inhibitor minimization and/or avoidance are warranted to clearly confirm the short and long-term safety and efficacy of alternative immunosuppression combinations. Linked pharmacokinetic and mechanistic studies within these trials will allow for optimizing drug dosing and monitoring. This article reviews published experience to date with steroid and calcineurin minimization in pediatric renal transplantation and discusses the risks and benefits of these approaches. 相似文献